We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+11.03%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$10.6B
AUM Growth
+$1.17B
(+12%)
Cap. Flow
+$3.01B
Cap. Flow
% of AUM
28.27%
Top 10 Holdings %
Top 10 Hldgs %
22.3%
Holding
850
New
52
Increased
273
Reduced
342
Closed
48
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$96.9M |
| 2 |
Merck
MRK
|
+$73.5M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$57.1M |
| 4 |
Illumina
ILMN
|
+$40.4M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$34.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$57.2M |
| 2 |
IMMU
Immunomedics Inc
IMMU
|
+$51.7M |
| 3 |
Kimberly-Clark
KMB
|
+$28.5M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
+$26.5M |
| 5 |
Arista Networks
ANET
|
+$22.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 35.77% |
| 2 | Technology | 20.35% |
| 3 | Consumer Discretionary | 9.49% |
| 4 | Communication Services | 7.69% |
| 5 | Financials | 7.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALLK
251
DELISTED
Allakos
ALLK
| $9.11M | 0.09% |
111,872
| – | – |
|
|
AIMT
252
DELISTED
Aimmune Therapeutics
AIMT
| $9.05M | 0.09% |
+262,804
| New | +$5.6M |
|
253
Goldman Sachs
GS
$302B
| $9.05M | 0.09% |
45,025
+393
| +0.9% | +$80K |
|
|
IMMU
254
DELISTED
Immunomedics Inc
IMMU
| $9.04M | 0.09% |
106,369
-1,022,263
| -91% | -$51.7M |
|
255
Restaurant Brands International
QSR
$25.8B
| $8.85M | 0.08% |
154,631
+59,267
| +62% | +$3.31M |
|
|
KSU
256
DELISTED
Kansas City Southern
KSU
| $8.55M | 0.08% |
47,278
-7,369
| -13% | -$1.28M |
|
257
Mondelez International
MDLZ
$80.5B
| $8.46M | 0.08% |
147,236
-13,614
| -8% | -$758K |
|
258
McCormick & Company Non-Voting
MKC
$13.7B
| $8.44M | 0.08% |
87,006
-31,094
| -26% | -$3.04M |
|
259
Stanley Black & Decker
SWK
$14.9B
| $8.4M | 0.08% |
51,766
+33,232
| +179% | +$5.17M |
|
260
Arcus Biosciences
RCUS
$3.55B
| $8.38M | 0.08% |
488,670
+265,728
| +119% | +$5.94M |
|
261
Fastenal
FAST
$53.5B
| $8.29M | 0.08% |
367,920
+287,794
| +359% | +$6.61M |
|
262
Power Integrations
POWI
$3.39B
| $8.21M | 0.08% |
148,198
+13,924
| +10% | +$802K |
|
|
CLVS
263
DELISTED
Clovis Oncology, Inc.
CLVS
| $8.08M | 0.08% |
1,385,635
+87,185
| +7% | +$522K |
|
264
Principal Financial Group
PFG
$24.5B
| $8.04M | 0.08% |
199,784
+33,419
| +20% | +$1.42M |
|
|
CNST
265
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $7.89M | 0.07% |
389,320
-5,332
| -1% | -$130K |
|
266
Idexx Laboratories
IDXX
$44.1B
| $7.84M | 0.07% |
19,956
-5,258
| -21% | -$1.94M |
|
267
Cognizant
CTSH
$24.3B
| $7.81M | 0.07% |
112,570
-9,777
| -8% | -$636K |
|
268
Fidelity National Information Services
FIS
$23.8B
| $7.78M | 0.07% |
52,829
-1,420
| -3% | -$205K |
|
269
Immunovant
IMVT
$8.11B
| $7.74M | 0.07% |
220,000
+80,000
| +57% | +$2.41M |
|
270
Parker-Hannifin
PH
$121B
| $7.7M | 0.07% |
38,041
+10,125
| +36% | +$1.99M |
|
271
Karyopharm Therapeutics
KPTI
$159M
| $7.64M | 0.07% |
34,891
+17,593
| +102% | +$4.3M |
|
272
Arvinas
ARVN
$536M
| $7.58M | 0.07% |
320,966
-43,319
| -12% | -$1.26M |
|
273
Monster Beverage
MNST
$95.5B
| $7.55M | 0.07% |
188,248
-24,186
| -11% | -$955K |
|
274
HDFC Bank
HDB
$124B
| $7.48M | 0.07% |
299,330
-207,332
| -41% | -$5.03M |
|
275
AutoZone
AZO
$49.1B
| $7.47M | 0.07% |
6,340
-705
| -10% | -$833K |
|
Similar funds
PCM
A
MGP
LF
BPA
MIM
SPIA
Candriam SCA's Q3 2020 Portfolio in Review
As of Q3 2020, Candriam SCA held 850 positions worth $10.6B, up 12% from $9.47B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Candriam SCA deployed $3.01B of net new capital in Q3 2020, opening 52 new positions and adding to 273 existing holdings. Its largest new stake was VIVINT SOLAR, INC.: 840,936 shares worth $35.6M.
By sector, the portfolio is most concentrated in Healthcare at 36% of assets, up from 35% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Apple, an estimated $57.2M trimmed.
- Candriam SCA's largest Q3 2020 buy was VIVINT SOLAR, INC.: 840,936 shares worth $35.6M.
- Candriam SCA added most to Amgen in Q3 2020, an estimated $96.9M increase.
- Candriam SCA's biggest Q3 2020 reduction was Apple, cutting an estimated $57.2M.
- Candriam SCA fully exited G1 Therapeutics, Inc. Common Stock in Q3 2020, selling an estimated $21.1M.
- Candriam SCA's ten largest holdings make up 22% of its $10.6B portfolio in Q3 2020.
- Candriam SCA opened 52 new positions and closed 48 in Q3 2020.
- Candriam SCA's portfolio value rose 12% quarter-over-quarter to $10.6B.
Based on Candriam SCA's 13F filing for Q3 2020, filed 19 Oct 2020.